Goldman Sachs Upgrades Teva Pharma (TEVA) to Buy
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $12.92 +0.31%
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
Goldman Sachs upgraded Teva Pharma (NYSE: TEVA) from Neutral to Buy with a price target of $75.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $61.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades First Solar (FSLR) to Outperform
- UBS Upgrades Hirose Electric (6806:JP) (HRSEF) to Neutral
- Roth/MKM Upgrades Albertsons Companies Inc. (ACI) to Buy, 'Fundamental Floor and Improved Deal Likelihood'
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
